Navidea Biopharmaceuticals Inc
NAVB
Get informed when a big investor buys or sells
+ FollowMarket Cap$10.01K
Close$
$-0.02
18600% downside
Current Fair Value
18600% downsideOvervalued by 18600% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $10,008.00 |
|---|---|
| Enterprise Value | $-1,795,051.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.59 |
| Beta | 1.8 |
| Outstanding Shares | 99,364,154 |
Return
| Return on Equity | 15.27% |
|---|---|
| Return on Assets | -8.77% |
| Return on Invested Capital | 463.27% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | -0.0 |
| Enterprise Value to Revenue | -2942.71 |
| Enterprise Value to EBIT | 0.17 |
| Enterprise Value to Net Income | 3 |
| Total Debt to Enterprise | -1.15 |
| Debt to Equity | -0.63 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Navidea Biopharmaceuticals Inc
CEO: Jed Latkin